TARGETING more patients
Our pipeline
With a focus on novel cell therapies for cancer, Chimeric currently has three novel cell therapies in four human clinical trials.
Our first asset, CHM CDH17, is in clinical trials for gastric and neuroendocrine cancers and colorectal cancers. Our second asset, CHM CLTX, is being applied to the brain cancer, Glioblastoma. And finally, with our third platform, the CHM CORE NK platform, we're addressing the blood cancer, AML, as well as testing in patients with colorectal cancer.
BUILDING A CELL THERAPY PORTFOLIO
T cells & NK Cells
Cell therapy (also called cellular therapy, cell transplantation, or cytotherapy) is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T cells or NK cells capable of fighting cancer cells via cell-mediated immunity.
